published meta-analysis   sensitivity analysis   studies

sarilumab in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] 1.09[0.56; 2.12]Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202120%500moderatenot evaluable clinical improvementdetailed resultsLescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] 1.03[0.75; 1.41]Lescure (Sarilumab 200mg), 202110%247NAnot evaluable clinical improvement (time to event analysis only)detailed resultsLescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] 1.09[0.87; 1.35]Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202120%506moderatenot evaluable serious adverse eventsdetailed resultsLescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] 1.26[0.82; 1.94]Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202120%502moderatenot evaluable adverse eventsdetailed resultsLescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] 1.13[0.77; 1.67]Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 202120%502moderatenot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-29 14:03 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 553,628,646,645 - roots T: 290